Cargando…

A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study

BACKGROUND: Public policy and clinical treatment in tobacco addiction in the UK has focused on cessation: an abrupt attempt to stop all cigarettes. However, recent evidence suggests that allowing more gradual withdrawal from tobacco or even permanent partial substitution by nicotine replacement ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Taskila, Taina, MacAskill, Susan, Coleman, Tim, Etter, Jean-Francois, Patel, Mahendra, Clarke, Sarah, Bridson, Rachel, Aveyard, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368776/
https://www.ncbi.nlm.nih.gov/pubmed/22410103
http://dx.doi.org/10.1186/1471-2458-12-182
_version_ 1782234988287098880
author Taskila, Taina
MacAskill, Susan
Coleman, Tim
Etter, Jean-Francois
Patel, Mahendra
Clarke, Sarah
Bridson, Rachel
Aveyard, Paul
author_facet Taskila, Taina
MacAskill, Susan
Coleman, Tim
Etter, Jean-Francois
Patel, Mahendra
Clarke, Sarah
Bridson, Rachel
Aveyard, Paul
author_sort Taskila, Taina
collection PubMed
description BACKGROUND: Public policy and clinical treatment in tobacco addiction in the UK has focused on cessation: an abrupt attempt to stop all cigarettes. However, recent evidence suggests that allowing more gradual withdrawal from tobacco or even permanent partial substitution by nicotine replacement therapy (NRT) could lead to net benefits to public health. No jurisdiction has introduced smoking reduction programmes in normal clinical care and the best methods for their implementation is uncertain. Community pharmacists offering smoking cessation services in the UK are ideally placed to implement reduction programmes. This pilot study aims therefore to examine the feasibility of implementing smoking reduction programme in pharmacies, and also to see if behavioural support and a longer treatment affect the success rate for cessation. DESIGN AND METHODS: This is a 2 × 2 randomised factorial trial of behavioural support versus no support and short versus standard length reduction programme. The pharmacists will recruit 16 patients per pharmacy, 160 smokers altogether. Pharmacists will randomise each participant by sealed envelopes. In a standard supported programme, the pharmacist will give support for 34 weeks, inviting participants to set a treatment goal and providing advice on how to reduce cigarette use. Participants in the short programme will be given the same advice on how to reduce but will reduce smoking over four weeks. Participants in the no support arms will be given a leaflet that describes the reduction programmes in 4-week and 34-week format. All participants are encouraged to use of NRT to support the reduction. These processes will be measured by recording the number of recruited smokers; percentage of those who reduce and sustain their consumption to at least 50% of baseline value, and the proportion of people who attain 4 weeks abstinence and 6 months abstinence. Interviews will assess smokers' and pharmacists' views on the way the programme ran. DISCUSSION: This is a pilot study to assess the feasibility of offering smoking reduction programme within pharmacies that offer naturalistic setting to show population benefit from these programmes. Findings from this trial will inform the development of evidence-based treatment for smokers who want to reduce and best approaches to engage reluctant quitters onto the programme. TRIAL REGISTRATION: Current Controlled Trials ISRCTN 2010-019259-24
format Online
Article
Text
id pubmed-3368776
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33687762012-06-07 A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study Taskila, Taina MacAskill, Susan Coleman, Tim Etter, Jean-Francois Patel, Mahendra Clarke, Sarah Bridson, Rachel Aveyard, Paul BMC Public Health Study Protocol BACKGROUND: Public policy and clinical treatment in tobacco addiction in the UK has focused on cessation: an abrupt attempt to stop all cigarettes. However, recent evidence suggests that allowing more gradual withdrawal from tobacco or even permanent partial substitution by nicotine replacement therapy (NRT) could lead to net benefits to public health. No jurisdiction has introduced smoking reduction programmes in normal clinical care and the best methods for their implementation is uncertain. Community pharmacists offering smoking cessation services in the UK are ideally placed to implement reduction programmes. This pilot study aims therefore to examine the feasibility of implementing smoking reduction programme in pharmacies, and also to see if behavioural support and a longer treatment affect the success rate for cessation. DESIGN AND METHODS: This is a 2 × 2 randomised factorial trial of behavioural support versus no support and short versus standard length reduction programme. The pharmacists will recruit 16 patients per pharmacy, 160 smokers altogether. Pharmacists will randomise each participant by sealed envelopes. In a standard supported programme, the pharmacist will give support for 34 weeks, inviting participants to set a treatment goal and providing advice on how to reduce cigarette use. Participants in the short programme will be given the same advice on how to reduce but will reduce smoking over four weeks. Participants in the no support arms will be given a leaflet that describes the reduction programmes in 4-week and 34-week format. All participants are encouraged to use of NRT to support the reduction. These processes will be measured by recording the number of recruited smokers; percentage of those who reduce and sustain their consumption to at least 50% of baseline value, and the proportion of people who attain 4 weeks abstinence and 6 months abstinence. Interviews will assess smokers' and pharmacists' views on the way the programme ran. DISCUSSION: This is a pilot study to assess the feasibility of offering smoking reduction programme within pharmacies that offer naturalistic setting to show population benefit from these programmes. Findings from this trial will inform the development of evidence-based treatment for smokers who want to reduce and best approaches to engage reluctant quitters onto the programme. TRIAL REGISTRATION: Current Controlled Trials ISRCTN 2010-019259-24 BioMed Central 2012-03-12 /pmc/articles/PMC3368776/ /pubmed/22410103 http://dx.doi.org/10.1186/1471-2458-12-182 Text en Copyright ©2012 Taskila et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Taskila, Taina
MacAskill, Susan
Coleman, Tim
Etter, Jean-Francois
Patel, Mahendra
Clarke, Sarah
Bridson, Rachel
Aveyard, Paul
A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
title A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
title_full A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
title_fullStr A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
title_full_unstemmed A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
title_short A randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
title_sort randomised trial of nicotine assisted reduction to stop in pharmacies - the redpharm study
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368776/
https://www.ncbi.nlm.nih.gov/pubmed/22410103
http://dx.doi.org/10.1186/1471-2458-12-182
work_keys_str_mv AT taskilataina arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT macaskillsusan arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT colemantim arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT etterjeanfrancois arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT patelmahendra arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT clarkesarah arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT bridsonrachel arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT aveyardpaul arandomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT taskilataina randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT macaskillsusan randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT colemantim randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT etterjeanfrancois randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT patelmahendra randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT clarkesarah randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT bridsonrachel randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy
AT aveyardpaul randomisedtrialofnicotineassistedreductiontostopinpharmaciestheredpharmstudy